AI
Thursday, December 23, 2010 2:29:27 PM
I rarely even look at any of the Yahoo boards (before I'm accused of being a Cramer-loving Yahooligan 
) but I was curious to see what their Teva board had to say.
Two posts seem to sum it up. Representative of many, one poster asserts:
"The news supports what Teva has been claiming all along."
This is answered by a more clear-thinking realist:
"Today's CRL does not support anything TEVA is claiming except it will have trouble getting its lower-volume injection Copaxone approved.
MNTA can fully characterize Copaxone. Lovenox is a much more complicated molecule to replicate than Copaxone. MNTA will get approval for Copaxone however the most important question is when and what will happen with the patent lawsuit.
Anyone buying TEVA thinking today's news is going to hurt MNTA's chance of obtaining generic approval for Copaxone is making a mistake."
) but I was curious to see what their Teva board had to say. Two posts seem to sum it up. Representative of many, one poster asserts:
"The news supports what Teva has been claiming all along."
This is answered by a more clear-thinking realist:
"Today's CRL does not support anything TEVA is claiming except it will have trouble getting its lower-volume injection Copaxone approved.
MNTA can fully characterize Copaxone. Lovenox is a much more complicated molecule to replicate than Copaxone. MNTA will get approval for Copaxone however the most important question is when and what will happen with the patent lawsuit.
Anyone buying TEVA thinking today's news is going to hurt MNTA's chance of obtaining generic approval for Copaxone is making a mistake."
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
